

THE SYNTHESIS AND BIOLOGICAL  
ACTIVITY OF A NOVEL SERIES  
OF 2-ARYL PENEMS

Sir:

The penems are a series of synthetically prepared  $\beta$ -lactam derivatives which were initially designed<sup>1)</sup> by combining the structural features of both the 5-membered thiazoline ring of the penicillins with the enamine-like double bond of the cephalosporins. Further introduction of a 6*S*-(1*R*-hydroxyethyl) substituent, found in the carbapenem thienamycin, to the corresponding position in the penem nucleus has resulted in highly potent and broad spectrum antibiotics. We now wish to report the investigation of a new series of penems which bear a substituted phenyl group in the 2-position. It has been found that the level of potency of these compounds depends critically on the nature of the substituent on the phenyl ring.


Much attention has been paid to penems with a variety of substituents in the 2-position, particularly 2-alkylthio<sup>2)</sup>, 2-thiomethyl<sup>3)</sup>, 2-oxymethyl<sup>4)</sup> and 2-aryloxy<sup>5)</sup>. Conversely, until recently<sup>6,7)</sup>, only scant attention has been paid to 2-arylpenems despite the fact that a 2-phenylpenem was one of the first examples prepared<sup>1)</sup>. We sought therefore to investigate such a series of 2-arylpenems and in particular to vary the nature of the substituent on the phenyl ring. Furthermore, our experience in the 2-aryloxyphenem series<sup>5)</sup> suggested that a carbamoyl-phenyl penem might be a highly potent antibacterial agent and was therefore an especially attractive target.

A short and high-yielding route to the arylpenem nucleus was required. It was reasoned that if the recently discovered oxalimide cyclization<sup>8)</sup> could be employed for the 2-aryl series then the readily available thiobenzoic acids (from benzoyl chlorides and H<sub>2</sub>S) would provide convenient starting materials for such a route. Thus, reaction of the well known *tert*-butyldimethylsilyl (TBDMS)-protected acetoxyazetidinone (1)<sup>9)</sup> with the thiobenzoic acids (2), as their sodium salts, gave the intermediate thioesters (3) in good yields. These thioesters all exhibited a large coupling constant between 3-H and 4-H ( $J=2.3\sim 2.5$  Hz) indicating a *trans* configuration across the ring and confirming that displacement of the acetoxy group occurs with retention of stereochemistry. Acylation of the azetidinone NH with *para*-nitrobenzyl (PNB) oxalyl chloride afforded the desired oxalimide intermediates (4), which

could be isolated but were not stable to chromatography on silica gel. Direct treatment of the oxalimides (4) with two equivalents of triethyl phosphite in refluxing xylene smoothly afforded the protected penems (5) in good to excellent yields. These were subsequently desilylated with tetrabutylammonium fluoride and the resulting penem PNB-esters (6) hydrogenated to provide the desired penems (7), which were isolated as their potassium salts. While this route worked very well for the unsubstituted phenyl penem (7a) and for a variety of simple substituents (7b~7f), and indeed even for the secondary amide penems (7g and 7h) it failed completely to provide the sought-after primary amide (7i). It appeared that although the primary amide intermediate (3i) could be obtained its acylation with PNB-oxalyl chloride was complex, presumably because of competing acylation at both the azetidinone NH and the primary amide, and none of the cyclized product (5i) was obtained. In fact, during some attempts at this reaction small amounts of the cyanopenem (5k) were isolated providing an indication that reaction had occurred at the amide group.

A less direct route to the primary amide, which utilized a protected carboxyl strategy, was therefore adopted. The half ester-half thioacid (2m), in which the latent carbamoyl function is protected as a 3,4-dimethoxybenzyl (DMB) ester<sup>10)</sup>, was carried through the sequence and the penem DMB-ester (6m) obtained in good yields. Deprotection of the DMB moiety using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone<sup>10)</sup> provided the penem free carboxylic acid (6n) and conversion of the acid to the primary amide (6i) was accomplished by a simple activated ester strategy. Thus, the free acid (6n) was reacted with 1-hydroxybenzotriazole in acetonitrile, using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide as a coupling reagent. The resulting active ester was treated with a solution of ammonia in acetonitrile to provide the desired amide (6i) cleanly, and in good yield.

The *meta*-carbamoylphenyl penem (6q) was obtained by a similar sequence starting with the DMB-ester (2p) and both amide PNB-esters (6i and 6q) were deprotected in the usual manner to give the amide potassium salts (7i and 7q), respectively, (7i: <sup>1</sup>H NMR (250 MHz, D<sub>2</sub>O)  $\delta$  7.80, 7.50 (4H, ABq, ArH), 5.79 (1H, d,  $J_{5,6}=1.1$  Hz, 5-H), 4.26 (1H, m, CHCH<sub>3</sub>), 3.99 (1H, dd,  $J_{5,6}=1.1$  Hz and  $J_{6,8}=5.9$  Hz, 6-H), 1.30 (3H, d,  $J_{8,9}=6.3$  Hz, CHCH<sub>3</sub>) and (7q: <sup>1</sup>H NMR (250 MHz, D<sub>2</sub>O)  $\delta$  7.77



Reagents: i) NaOH, acetone; ii) ClCOCOOPNB, (2-Pr)<sub>2</sub>NEt, CaCO<sub>3</sub>, dichloromethane; iii) P(OEt)<sub>3</sub>, xylene, reflux; iv) (Bu)<sub>4</sub>NF, AcOH, THF; v) H<sub>2</sub>, Pd-C, KHCO<sub>3</sub>, dioxane-water.

Table 1. *In vitro* antibacterial activities<sup>a</sup> of 2-aryl penems.

Organism	Compound				
	7a	7d	7e	7i	7q
	R=	H	4-OCH <sub>3</sub>	4-SCH <sub>3</sub>	4-CONH <sub>2</sub>
<i>Streptococcus pyogenes</i> A77	<0.05	<0.05	<0.05	0.01	0.01
<i>S. pyogenes</i> A308	<0.05	<0.05	<0.05	0.01	0.006
<i>S. faecium</i> MD8b	1.56	3.12	3.12	1.56	1.56
<i>Staphylococcus aureus</i> SG 511	0.1	0.1	ND	0.05	0.05
<i>S. aureus</i> 285 <sup>b</sup>	0.19	0.19	0.19	0.1	0.1
<i>S. aureus</i> 503 <sup>b</sup>	0.1	0.19	0.19	0.1	0.1
<i>Escherichia coli</i> O 55	0.78	0.19	6.25	0.19	0.1
<i>E. coli</i> DC0	3.12	25	50	0.78	0.39
<i>E. coli</i> DC2	0.39	0.78	0.78	0.39	0.1
<i>E. coli</i> TEM <sup>b</sup>	1.56	12.5	25	0.39	0.19
<i>E. coli</i> 1507 E	1.56	12.5	25	0.39	0.19
<i>E. coli</i> KN 126	3.12	12.5	12.5	0.39	0.1
<i>Klebsiella oxytoca</i> 1082 E <sup>b</sup>	0.78	0.78	0.78	0.39	0.1
<i>K. aerogenes</i> 1522 E	1.56	12.5	25	0.39	0.19
<i>Enterobacter cloacae</i> P99 <sup>b</sup>	12.5	100	50	6.25	1.56
<i>E. cloacae</i> 1321 E	1.56	12.5	12.5	0.39	0.1
<i>Salmonella typhi</i> MZ II	0.78	6.25	12.5	0.39	0.19

<sup>a</sup> MICs (μg/ml) were determined by standard 2-fold agar dilution in Mueller-Hinton agar.

<sup>b</sup> Indicates organism produces a β-lactamase.

ND: Not determined.

(2H, m, ArH), 7.60 (1H, dt, *J*=1.4 and 7.9 Hz, ArH), 7.48 (1H, t, *J*=8.0 Hz, ArH), 5.78 (1H, d, *J*<sub>5,6</sub>=1.5 Hz, 5-H), 4.25 (1H, m, CHCH<sub>3</sub>), 3.98 (1H,

dd, *J*<sub>5,6</sub>=1.5 Hz and *J*<sub>6,8</sub>=5.9 Hz, 6-H), 1.30 (3H, d, *J*<sub>8,9</sub>=6.3 Hz, CHCH<sub>3</sub>).

Having established a short, high-yielding route to

2-arylpemems and in particular to the carbamoyl derivatives (**7i** and **7q**) we now report that these compounds represent a new and very active series of antibacterials (see Table 1) and that the latter carbamoyl compounds are particularly potent. It is interesting to note that, while the results in Table 1 show that activity of this series of compounds appears to correlate with electron withdrawing ability of the substituent on the phenyl ring (e.g. **7i** > **7a** > **7d**), the *meta*-substituted amide (**7q**) is 2~4-fold more active than the corresponding *para*-amide (**7i**). Therefore, the critical effect that the nature of the substituent on the phenyl ring has to the antibacterial activity of these compounds cannot be explained solely in simple electronic terms.

#### Acknowledgements

We wish to acknowledge the advice and encouragement of Dr. BARRY ROSS at the outset of this project. We are grateful to Mr. STEVEN CLAMP and Mr. MICHAEL TURVILL for technical assistance.

STEPHEN CONNOLLY<sup>†</sup>  
 KEVIN W. MOORE<sup>††</sup>  
 MICHAEL D. COOKE  
 JOHN G. WALMSLEY  
 PETER H. BENTLEY

Hoechst Pharmaceutical Research Laboratories,  
 Milton Keynes, MK7 7AJ, UK

(Received May 7, 1991)

#### References

- WOODWARD, R. B.: Penems and related substances. *Philos. Trans. R. Soc. Lond. B* 289: 239~250, 1980
- OIDA, S.; A. YOSHIDA, T. HAYASHI, N. TAKEDA, T. NISHIMURA & E. OHKI: Synthesis of penems and their antibacterial activities. *J. Antibiotics* 33: 107~109, 1980
- FRANCESCHI, G.; M. ALPEGIANI, A. BEDESCHI, M. FOGGIO & E. PERRONE: A new class of penems, the 2-heterocyclyl(thio)methyl derivatives. *J. Antibiotics* 37: 685~688, 1980
- FRANCESCHI, G.; M. FOGGIO, M. ALPEGIANI, C. BATTISTINI, A. BEDESCHI, E. PERRONE, F. ZARINI, F. ARCAMONE, C. D. BRUNA & A. SANFILLIPPO: Synthesis and biological properties of sodium (5*R*,6*S*,8*R*)-6 $\alpha$ -hydroxyethyl-2-carbamoyloxymethyl-2-penem-3-carboxylate (FCE 22101) and its orally absorbed esters FCE 22553 and FCE 22891. *J. Antibiotics* 36: 938~941, 1983
- COOKE, M. D.; K. W. MOORE, B. C. ROSS & S. E. TURNER: Stereoselective synthesis of a (5*R*,6*S*)-6-[(*R*)-1-hydroxyethyl]-2-aryloxypenem. *J. Chem. Soc. Chem. Commun.* 1983: 1005~1006, 1983
- BEDESCHI, A.; G. VISENTIN, E. PERRONE, F. GIUDICI, F. ZARINI, G. FRANCESCHI, G. MEINARDI, P. CASTELLANI, D. JABES, R. ROSSI & C. DELLA BRUNA: Synthesis and structure-activity relations in the class of 2-(pyridyl)penems. *J. Antibiotics* 43: 306~313, 1990
- PERRONE, E.; M. ALPEGIANI, A. BEDESCHI, F. GIUDICI, F. ZARINI, G. FRANCESCHI, C. DELLA BRUNA, D. JABES & G. MEINARDI: Novel quaternary ammonium penems: The [(pyridinio)methyl]phenyl derivatives. *J. Antibiotics* 40: 1636~1639, 1987
- BATTISTINI, C.; C. SCARAFILE, M. FOGGIO & G. FRANCESCHI: A new route to penems and carbapenems. *Tetrahedron Lett.* 25: 2395~2398, 1984
- OIDA, S.: 27. Penems, synthetic approach to thienamycin analogues. *In Recent Advances in the Chemistry of  $\beta$ -Lactam Antibiotics. Special Publication No. 38. Ed., G. I. GREGORY, pp. 330~348, The Royal Society of Chemistry, 1981*
- KIM, C. U. & P. F. MISCO: New oxidatively removable carboxy protecting groups. *Tetrahedron Lett.* 26: 2027~2030, 1985

Present address: <sup>†</sup> Fisons Pharmaceuticals, Medicinal Chemistry, Bakewell Road, Loughborough, Leics, UK.

<sup>††</sup> Merck, Sharp & Dohme, Neuroscience Centre, Terlings Park, Harlow, Essex, UK.